Literature DB >> 16537612

Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen modulates K1 expression through its cis-acting elements within the terminal repeats.

Subhash C Verma1, Ke Lan, Tathagata Choudhuri, Erle S Robertson.   

Abstract

K1 is the first open reading frame encoded by Kaposi's sarcoma-associated herpesvirus (KSHV) and lies positionally to the immediate right of the terminal repeats. K1 is a transmembrane glycoprotein having a functional immunoreceptor tyrosine-based activation motif (ITAM) capable of activating B-cell receptor signaling. K1 is expressed mostly during the lytic cycle of the virus and its promoter lies within the terminal repeat which contains the binding sites for latency-associated nuclear antigen (LANA). The K1 promoter (K1p) having LANA binding sites assayed by reporter assay demonstrated that LANA is capable of down-regulating K1 promoter transcriptional activity. However, the KSHV replication transcription activator RTA up-regulates K1p transcriptional activity. The promoter deleted of LANA binding sites showed loss in LANA-mediated down-regulation but was unaffected for RTA-mediated up-regulation. Increasing amounts of RTA rescued LANA-mediated repression of K1p transcriptional activity in cotransfection experiments. Reporter assay data suggest that LANA binding to its cognate sequence is critical for LANA-mediated repression of K1p as a LANA construct lacking the DNA binding domain was unable to repress K1p transcription. Additionally, KSHV primary infection experiments suggest that K1 is expressed during early infection but is repressed on the establishment of latency and so follows an expression profile similar to that of RTA during infection. Analysis of the promoter sequence revealed the presence of Oct-1 transcription factor binding sites within the -116 to +76 region. Mutational analysis of the Oct-1 sites abolished RTA-mediated transcriptional activation, suggesting that RTA up-regulates K1p transcription through binding to this transcription factor.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16537612      PMCID: PMC1440413          DOI: 10.1128/JVI.80.7.3445-3458.2006

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  61 in total

1.  Kaposi's sarcoma-associated herpesvirus latent and lytic gene expression as revealed by DNA arrays.

Authors:  R G Jenner; M M Albà; C Boshoff; P Kellam
Journal:  J Virol       Date:  2001-01       Impact factor: 5.103

2.  p53 inhibition by the LANA protein of KSHV protects against cell death.

Authors:  J Friborg; W Kong; M O Hottiger; G J Nabel
Journal:  Nature       Date:  1999 Dec 23-30       Impact factor: 49.962

3.  High-level variability in the ORF-K1 membrane protein gene at the left end of the Kaposi's sarcoma-associated herpesvirus genome defines four major virus subtypes and multiple variants or clades in different human populations.

Authors:  J C Zong; D M Ciufo; D J Alcendor; X Wan; J Nicholas; P J Browning; P L Rady; S K Tyring; J M Orenstein; C S Rabkin; I J Su; K F Powell; M Croxson; K E Foreman; B J Nickoloff; S Alkan; G S Hayward
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

4.  HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma.

Authors:  N Dupin; T L Diss; P Kellam; M Tulliez; M Q Du; D Sicard; R A Weiss; P G Isaacson; C Boshoff
Journal:  Blood       Date:  2000-02-15       Impact factor: 22.113

5.  The latency-associated nuclear antigen tethers the Kaposi's sarcoma-associated herpesvirus genome to host chromosomes in body cavity-based lymphoma cells.

Authors:  M A Cotter; E S Robertson
Journal:  Virology       Date:  1999-11-25       Impact factor: 3.616

6.  The latent nuclear antigen of Kaposi sarcoma-associated herpesvirus targets the retinoblastoma-E2F pathway and with the oncogene Hras transforms primary rat cells.

Authors:  S A Radkov; P Kellam; C Boshoff
Journal:  Nat Med       Date:  2000-10       Impact factor: 53.440

Review 7.  Human herpesvirus-8-encoded signalling ligands and receptors.

Authors:  John Nicholas
Journal:  J Biomed Sci       Date:  2003 Sep-Oct       Impact factor: 8.410

8.  Global changes in Kaposi's sarcoma-associated virus gene expression patterns following expression of a tetracycline-inducible Rta transactivator.

Authors:  Hiroyuki Nakamura; Michael Lu; Yousang Gwack; John Souvlis; Steven L Zeichner; Jae U Jung
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

9.  ORF73 of herpesvirus Saimiri strain C488 tethers the viral genome to metaphase chromosomes and binds to cis-acting DNA sequences in the terminal repeats.

Authors:  Subhash C Verma; Erle S Robertson
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

10.  Inhibition of intracellular transport of B cell antigen receptor complexes by Kaposi's sarcoma-associated herpesvirus K1.

Authors:  B S Lee; X Alvarez; S Ishido; A A Lackner; J U Jung
Journal:  J Exp Med       Date:  2000-07-03       Impact factor: 14.307

View more
  23 in total

1.  Nm23-H1 can induce cell cycle arrest and apoptosis in B cells.

Authors:  Tathagata Choudhuri; Masanao Murakami; Rajeev Kaul; Sushil K Sahu; Suchitra Mohanty; Subhash C Verma; Pankaj Kumar; Erle S Robertson
Journal:  Cancer Biol Ther       Date:  2010-06-11       Impact factor: 4.742

Review 2.  Molecular biology of KSHV in relation to AIDS-associated oncogenesis.

Authors:  Whitney Greene; Kurt Kuhne; Fengchun Ye; Jiguo Chen; Fuchun Zhou; Xiufen Lei; Shou-Jiang Gao
Journal:  Cancer Treat Res       Date:  2007

3.  mRNA translation regulation by the Gly-Ala repeat of Epstein-Barr virus nuclear antigen 1.

Authors:  Sebastien Apcher; Anastassia Komarova; Chrysoula Daskalogianni; Yili Yin; Laurence Malbert-Colas; Robin Fåhraeus
Journal:  J Virol       Date:  2008-11-19       Impact factor: 5.103

4.  The ATM/ATR signaling effector Chk2 is targeted by Epstein-Barr virus nuclear antigen 3C to release the G2/M cell cycle block.

Authors:  Tathagata Choudhuri; Subhash C Verma; Ke Lan; Masanao Murakami; Erle S Robertson
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

Review 5.  The molecular biology of human herpesvirus-6 latency and telomere integration.

Authors:  Jesse H Arbuckle; Peter G Medveczky
Journal:  Microbes Infect       Date:  2011-03-31       Impact factor: 2.700

6.  Characterization of de novo lytic infection of dermal lymphatic microvascular endothelial cells by Kaposi's sarcoma-associated herpesvirus.

Authors:  Gavin Golas; Juan D Alonso; Zsolt Toth
Journal:  Virology       Date:  2019-07-31       Impact factor: 3.616

7.  Latency-associated nuclear antigen of Kaposi's sarcoma-associated herpesvirus recruits uracil DNA glycosylase 2 at the terminal repeats and is important for latent persistence of the virus.

Authors:  Subhash C Verma; Bharat G Bajaj; Qiliang Cai; Huaxin Si; Todd Seelhammer; Erle S Robertson
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

8.  The epigenetic landscape of latent Kaposi sarcoma-associated herpesvirus genomes.

Authors:  Thomas Günther; Adam Grundhoff
Journal:  PLoS Pathog       Date:  2010-06-03       Impact factor: 6.823

9.  Nucleophosmin phosphorylation by v-cyclin-CDK6 controls KSHV latency.

Authors:  Grzegorz Sarek; Annika Järviluoma; Henna M Moore; Sari Tojkander; Salla Vartia; Peter Biberfeld; Marikki Laiho; Päivi M Ojala
Journal:  PLoS Pathog       Date:  2010-03-19       Impact factor: 6.823

10.  Murine gammaherpesvirus 68 LANA acts on terminal repeat DNA to mediate episome persistence.

Authors:  Aline C Habison; Chantal Beauchemin; J Pedro Simas; Edward J Usherwood; Kenneth M Kaye
Journal:  J Virol       Date:  2012-08-22       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.